Business
Cannabics Pharmaceuticals Inc. CEO talks with Uptick Newswire’s Stock Day Podcast About Cancer Research in the Cannabinoid Sector
Cannabics Pharmaceuticals Inc. CEO talks with Uptick Newswire’s Stock Day Podcast About Cancer Research in the Cannabinoid Sector.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\nPHOENIX, Ariz., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) (the “Company”) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. CEO & Co-Founder, Eyal Barad, talked with Stock Day’s Everett Jolly.\n “Cannabics Pharmaceuticals started about 5 years ago and today is mostly focused on the palliative and anti-tumor effects cannabinoids with cancer,” explained Barad. “We are truly focused on cancer, both the side effects and anti-tumor effects which we have found to be effectives in our studies.” Jolly mentioned that many cannabis companies have come on Stock Day but rarely do they have a cancer centric focus. He asked Barad what his overall goal for fighting cancer would be. “We started a study about 4-years-ago with one of the leading science universities in Israel, where we did drug sensitivity with various cannabinoids and various cancers and this is what got us going because we found that various ratios of various cannabinoids have different apoptotic effects on different cancers” Barad went on to say after the study, they wrote patents on the subject and developed a lab in Israel. He said they hope to one day find specific combinations for specific cancers in specific people. Jolly then mentioned the company’s pilot study on anorexia. Barad said they have summarized the first process of the clinical trial and that the results have enticed them to go to the next level and expand the study. “In anorexic patients, we were able to improve the appetite and cause some weight gain,” explained Barad. “There was overall improvement in life quality for the patient. We are very excited about that.” Jolly then asked about Cannabics Pharmaceutical’s partnership with Seedo, a lab that has developed an automated robot for growing personalized medical marijuana in people’s homes. “We find that very exciting because we are able to tap in and collect a whole bunch of data from people and getting involved in what different strains are and how they are affecting different people,” said Barad. “One of the visions we have together i...